ADVENZYMES Stock Overview
Engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for ADVENZYMES from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Advanced Enzyme Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹344.45 |
| 52 Week High | ₹571.00 |
| 52 Week Low | ₹334.05 |
| Beta | 0.46 |
| 1 Month Change | -8.91% |
| 3 Month Change | -34.04% |
| 1 Year Change | -7.89% |
| 3 Year Change | 3.45% |
| 5 Year Change | 108.88% |
| Change since IPO | 25.24% |
Recent News & Updates
Recent updates
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Aug 20
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Jul 19Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Shareholder Returns
| ADVENZYMES | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -3.4% | -0.6% | 0.2% |
| 1Y | -7.9% | 2.6% | 17.2% |
Return vs Industry: ADVENZYMES underperformed the Indian Chemicals industry which returned 2.6% over the past year.
Return vs Market: ADVENZYMES underperformed the Indian Market which returned 17.2% over the past year.
Price Volatility
| ADVENZYMES volatility | |
|---|---|
| ADVENZYMES Average Weekly Movement | 6.7% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: ADVENZYMES has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ADVENZYMES's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 323 | Mukund Kabra | www.advancedenzymes.com |
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids.
Advanced Enzyme Technologies Limited Fundamentals Summary
| ADVENZYMES fundamental statistics | |
|---|---|
| Market cap | ₹38.54b |
| Earnings (TTM) | ₹1.37b |
| Revenue (TTM) | ₹6.19b |
28.1x
P/E Ratio6.2x
P/S RatioIs ADVENZYMES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADVENZYMES income statement (TTM) | |
|---|---|
| Revenue | ₹6.19b |
| Cost of Revenue | ₹1.51b |
| Gross Profit | ₹4.69b |
| Other Expenses | ₹3.32b |
| Earnings | ₹1.37b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.25 |
| Gross Margin | 75.69% |
| Net Profit Margin | 22.13% |
| Debt/Equity Ratio | 1.8% |
How did ADVENZYMES perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield42%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 18:11 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Advanced Enzyme Technologies Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| null null | DBS Bank Ltd |
| Dhananjay Sinha | Emkay Global Financial Services Ltd. |